true
true

BD MAX™ Club

Transform the molecular diagnostic journey in partnership with the BD MAX™ System

Background Image

Maximize your experience on the BD MAX™ System

 

Alt text for image card

BD MAX™ Club was designed with your lab in mind. Every BD MAX™ user has the potential to become a catalyst of quality and innovation in molecular diagnostics, and BD MAX™ Club is the one-stop shop of resources that will help get you there.


As a BD MAX™ Club member, you have access to a wealth of exclusive on-demand content. Read a compelling scientific study, listen to a webinar from a leading industry expert, watch a tutorial video on BD MAX™ — and much, much more.


Grow your professional network and exchange with industry experts at BD MAX™ CLUB member events to take your diagnostic potential to the next level.

 

 

Why join BD MAX™ Club?

Connect with professionals from around the world

BD MAX™ Club members represent a community of professionals in infectious diseases and molecular diagnostics. With regional meet-ups and live webinars from global experts, expand your laboratory’s network and collaborate with worldwide colleagues.

Tailored medical and technical expertise

Whether you need compelling scientific research or tutorials for troubleshooting on the BD MAX™ System, BD MAX™ Club is here to accompany your molecular diagnostics journey. Access the BD MAX™ Club anywhere, anytime to view our information database.

Exclusive members’ perks

BD MAX™ Club membership unlocks doors to exclusive webinars and collaboration with industry leading experts. Engage with your colleagues in the molecular community and exchange with the BD research and development team.

BD MAX™ Resources

Solutions portfolio on BD MAX™ System to meet your diverse molecular testing needs.

 

 

BD MAX™ Scientific content

 

May 2015  |  Joel E Mortensen, Cindi Ventrola, Sarah Hanna, Adam Walter

Conventional bacterial stool culture is one of the more time-consuming tests in a routine clinical microbiology laboratory. In addition, less than 5 % of stool cultures yield positive results. A molecular platform, the BD MAX™ System (BD Diagnostics, Sparks, MD) offers the potential for significantly more rapid results and less hands-on time. Time-motion analysis of the BD MAX™ Enteric Bacterial Panel (EBP) (BD Diagnostics, Quebec, Canada) on the BD MAX™ System was compared to conventional stool culture in the microbiology laboratory of a tertiary care pediatric hospital.

Methods: The process impact analysis of time-motion studies of conventional cultures were compared to those of EBP with 86 stool specimens. Sample flow, hands-on time, processing steps, and overall turnaround time were determined and analyzed. Data were obtained and analyzed from both standard operating procedures and direct observation. A regression analysis was performed to ensure consistency of measurements. Time and process measurements started when the specimens were logged into the accessioning area of the microbiology laboratory and were completed when actionable results were generated.

Results: With conventional culture, negative culture results were available from 41:14:27 (hours:minutes:seconds) to 54:17:19; with EBP, positive and negative results were available from 2:28:40 to 3:33:39.

Conclusions: This study supports the suggestion that use of the EBP to detect commonly encountered stool pathogens can result in significant time savings and a shorter time-to-result for patients with acute bacterial diarrhea.

Read Full Article

August 2020  Giannoula S Tansarli, Lindsay LeBlanc, Dianne B Auld, Kimberle C Chapin

Abstract: Nasal colonization with Staphylococcus aureus is a well-referenced risk factor for postoperative surgical site infections (SSIs). Our health care system that performs >40,000 surgeries per year assessed both the diagnostic accuracy of the BD MAX™ StaphSR assay (MAX StaphSR), a PCR-based test that detects and differentiates S. aureus and methicillin-resistant S. aureus (MRSA), compared with our standard of care culture and the subsequent clinical impact on SSIs 1 year after implementation. In addition, residual specimens were tested by broth-enriched culture. Performance parameters for all methods were determined using latent class analysis. Direct culture was the least sensitive for S. aureus (85.1%) and MRSA (76.7%), whereas the MAX StaphSR assay and broth-enriched culture had similar sensitivities (96.7%) for MRSA. Prospective assessment using MAX StaphSR during a 1-year, postimplementation period revealed a lower rate of SSIs per 100 targeted surgeries (0.3) compared with MRSA-only screening (1.10) and no screening (2.28) (P < 0.05 for StaphSR versus MRSA-only screening and StaphSR versus no testing). MRSA and methicillin-sensitive S. aureus SSIs occurred equally (n = 14 each). The MAX StaphSR assay provided accurate detection of both S. aureus and MRSA nasal colonization in presurgical patients, allowing infection prevention measures, including presurgical prophylaxis, to be implemented in a timely and consistent manner to avoid SSIs.

Copyright © 2020 Association for Molecular Pathology and American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.

Read Full Article

April 2017  Sanjay R Mehta, Jasmine Estrada, Juan Ybarra, Joshua Fierer

Abstract: Introduction: Variation in MRSA genotypes may affect the sensitivity of molecular assays to detect this organism.

Methods: We compared 2 commonly used screening assays, the Cepheid™ Xpert® MRSA and the BD MAX™ MRSA XT on consecutively obtained nasal swabs from 479 subjects. Specimens giving discordant results were subjected to additional microbiologic and molecular testing.

Results: Six hundred forty-two (97.6%) of the 658 test results were concordant. Of the 16 discordant results from 12 subjects, additional results suggested that 9 (60%) of the 15 MRSA XT assays were likely correct, and 6 (40%) of the 15 Xpert® assays were likely correct. One discordant result could not be resolved. A mecA dropout and novel mec right-extremity junction (MREJ) sites led to false-positive and negative results by Xpert®.

Conclusion: While both assays performed well, continued vigilance is needed to monitor for Staphylococcus aureus with novel MREJ sites, mecA dropouts, and mecC, leading to inaccurate results in screening assays.

Read Full Article

BD MAX™ Videos

Get inspired by our BD MAX™ video library

BD MAX™ System and Assays
  • BD MAX™ System and Assays
  • BD MAX™ StaphSR Assays
  • BD MAX™ Specimen Collection Vaginal Panel
  • BD MAX™ Enteric Viral Panel

BD MAX™ Club Newsroom

Newspaper_Darkblue_Outline_32x32.svg
Cervical Cancer Screening


Women in U.S. Can Now Collect Their Own Sample for Cervical Cancer Screening


May 15, 2024 | BD announced U.S. FDA approval for the use of self-collected vaginal specimens for HPV testing when cervical specimens cannot otherwise be obtained...

Read more
<p>BD MAX™ Events</p>

BD MAX™ Events

 

06-15-2024  |   Atlanta, GA
ASM Microbe 2024 conference

 


 

06-15-2024  |   Atlanta, GA
ASM Microbe 2024 conference BD Sponsored Dinner event

 


 

6-25-2024  |   1pm PDT&  |   Molecular GI Testing Webinar
Advancing diagnostic stewardship and optimizing patient management

 


 

Watch On-demand  |   GI Testing Webinar
Simplify Your Gastrointestinal Testing with Real-Time PCR

 


 

7-28-2024  |   Chicago, IL
ADLM 2024 conference

 


Get in touch with a BD representative

Chat with us
Our live chat is available between the hours of 8.30am - 5.00pm EST, Monday - Friday
×

The BD MAX™ System, BD MAX™ Enteric Bacterial & Extended Enteric Bacterial Panels, BD MAX™ Enteric Viral Panel, BD MAX™ Enteric Viral Panel-NR, BD MAX™ Enteric Parasite Panel, BD MAX™ Vaginal Panel, BD MAX™ Check-Points CPO, BD MAX™ MRSA XT, BD MAX™ StaphSR, BD MAX™ Cdiff, BD MAX™ MDR-TB, BD SARS-CoV-2 Reagents for BD MAX™ System, BD SARS-CoV-2/Flu for BD MAX™ System, VIASURE SARS-CoV-2 (N1+N2) Real Time PCR Detection Kit for BD MAX™ System, VIASURE SARS-CoV-2 Variant Real Time PCR Detection Kit for BD MAX™, VIASURE SARS-CoV-2 Variant II Real Time PCR Detection Kit for BD MAX™, VIASURE SARS-CoV-2, Flu (A+B), RSV Real Time PCR Detection Kit for BD MAX™ System, VIASURE Flu A, Flu B & RSV Real Time PCR Detection Kit for BD MAX™ System, VIASURE VanR Time PCR Detection Kit for BD MAX™ System, are in vitro diagnostic medical devices bearing a CE mark.

The BD CTGCTV2 and BD CTGC2 for BD MAX™ System are in vitro diagnostic medical devices bearing a CE mark and are CE certified by BSI Group The Netherlands B.V. (Notified Body Number = 2797).